JP2015166379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015166379A5 JP2015166379A5 JP2015102945A JP2015102945A JP2015166379A5 JP 2015166379 A5 JP2015166379 A5 JP 2015166379A5 JP 2015102945 A JP2015102945 A JP 2015102945A JP 2015102945 A JP2015102945 A JP 2015102945A JP 2015166379 A5 JP2015166379 A5 JP 2015166379A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- unit dosage
- less
- naproxen
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 28
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 16
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 16
- 229960002009 naproxen Drugs 0.000 claims 16
- 239000002245 particle Substances 0.000 claims 14
- 239000011159 matrix material Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 5
- 238000004090 dissolution Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 5
- 239000007962 solid dispersion Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229960004977 anhydrous lactose Drugs 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 229960001855 mannitol Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000009837 dry grinding Methods 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17228909P | 2009-04-24 | 2009-04-24 | |
| AU2009901746 | 2009-04-24 | ||
| AU2009901746A AU2009901746A0 (en) | 2009-04-24 | A Novel Formulation of Naproxen | |
| US61/172,289 | 2009-04-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506288A Division JP6116244B2 (ja) | 2009-04-24 | 2010-04-23 | ナプロキセンの新規製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015166379A JP2015166379A (ja) | 2015-09-24 |
| JP2015166379A5 true JP2015166379A5 (enExample) | 2015-11-12 |
| JP6177275B2 JP6177275B2 (ja) | 2017-08-09 |
Family
ID=43010609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506288A Active JP6116244B2 (ja) | 2009-04-24 | 2010-04-23 | ナプロキセンの新規製剤 |
| JP2015102945A Expired - Fee Related JP6177275B2 (ja) | 2009-04-24 | 2015-05-20 | ナプロキセンの新規製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506288A Active JP6116244B2 (ja) | 2009-04-24 | 2010-04-23 | ナプロキセンの新規製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20120148634A1 (enExample) |
| EP (1) | EP2421512A4 (enExample) |
| JP (2) | JP6116244B2 (enExample) |
| KR (3) | KR20160135370A (enExample) |
| CN (2) | CN102438592B (enExample) |
| AP (1) | AP3530A (enExample) |
| AU (1) | AU2010239085C1 (enExample) |
| CA (1) | CA2759122A1 (enExample) |
| CO (1) | CO6470806A2 (enExample) |
| EA (1) | EA201171284A1 (enExample) |
| IL (1) | IL215868A0 (enExample) |
| MA (1) | MA33299B1 (enExample) |
| MX (1) | MX344222B (enExample) |
| NZ (2) | NZ595985A (enExample) |
| SG (2) | SG175767A1 (enExample) |
| TN (1) | TN2011000536A1 (enExample) |
| UA (1) | UA111578C2 (enExample) |
| WO (1) | WO2010121326A1 (enExample) |
| ZA (1) | ZA201108648B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2054042B8 (en) | 2006-06-30 | 2020-06-10 | iCeutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| MY159208A (en) | 2009-04-24 | 2016-12-30 | Iceutica Pty Ltd | A novel formulation of indomethacin |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| WO2015179098A1 (en) | 2014-05-21 | 2015-11-26 | Integenx Inc. | Fluidic cartridge with valve mechanism |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| US11435340B2 (en) | 2014-06-09 | 2022-09-06 | Biometry Inc. | Low cost test strip and method to measure analyte |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| US10210410B2 (en) | 2014-10-22 | 2019-02-19 | Integenx Inc. | Systems and methods for biometric data collections |
| US10690627B2 (en) | 2014-10-22 | 2020-06-23 | IntegenX, Inc. | Systems and methods for sample preparation, processing and analysis |
| CA3001337C (en) | 2015-10-09 | 2023-12-12 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| DK3411031T3 (da) | 2016-02-04 | 2024-10-21 | Cindome Pharma Inc | Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser |
| JP7086927B2 (ja) | 2016-07-19 | 2022-06-20 | バイオメトリー・インコーポレイテッド | バッチ校正可能なテストストリップを用いる検体測定方法と検体測定システム |
| JP7163015B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 経口固形組成物 |
| EP3613415B1 (en) * | 2017-04-21 | 2022-11-09 | Bio-Synectics Inc. | Method for preparing active material nanoparticles using lipid as lubricant for milling |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| US11779541B2 (en) * | 2019-03-26 | 2023-10-10 | Johnson & Johnson Consumer Inc. | Immediate release dosage form |
| TW202241409A (zh) * | 2020-12-18 | 2022-11-01 | 南韓商大熊製藥股份有限公司 | 包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之用於經口投予的新調配物 |
| KR20250112022A (ko) * | 2024-01-16 | 2025-07-23 | 피투케이바이오 주식회사 | 리바록사반 흡입용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US20030087308A1 (en) * | 2001-06-22 | 2003-05-08 | Elan Pharma International Limited | Method for high through put screening using a small scale mill or microfluidics |
| CA2858733C (en) * | 2004-12-31 | 2017-12-19 | Iceutica Pty Ltd | Nanoparticle compositions and methods for synthesis thereof |
| EP2054042B8 (en) * | 2006-06-30 | 2020-06-10 | iCeutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| US20100003332A1 (en) * | 2006-07-27 | 2010-01-07 | Amorepacific Corporation | Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| EA201171282A1 (ru) * | 2009-04-24 | 2012-05-30 | Айсьютика Пти Лтд. | Способ производства коммерческих порошков, содержащих нано- и микрочастицы |
| WO2010121321A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
| KR20150032759A (ko) * | 2009-04-24 | 2015-03-27 | 아이슈티카 피티와이 리미티드 | 큰 용적 분율로 캅셀화된 나노입자의 생산 |
-
2010
- 2010-04-23 UA UAA201113810A patent/UA111578C2/uk unknown
- 2010-04-23 AP AP2011005991A patent/AP3530A/xx active
- 2010-04-23 EA EA201171284A patent/EA201171284A1/ru unknown
- 2010-04-23 CA CA2759122A patent/CA2759122A1/en not_active Abandoned
- 2010-04-23 SG SG2011077476A patent/SG175767A1/en unknown
- 2010-04-23 CN CN201080017987.8A patent/CN102438592B/zh not_active Expired - Fee Related
- 2010-04-23 KR KR1020167032025A patent/KR20160135370A/ko not_active Ceased
- 2010-04-23 US US13/266,119 patent/US20120148634A1/en not_active Abandoned
- 2010-04-23 WO PCT/AU2010/000470 patent/WO2010121326A1/en not_active Ceased
- 2010-04-23 EP EP10766519A patent/EP2421512A4/en not_active Withdrawn
- 2010-04-23 MX MX2011011220A patent/MX344222B/es active IP Right Grant
- 2010-04-23 MA MA34386A patent/MA33299B1/fr unknown
- 2010-04-23 NZ NZ595985A patent/NZ595985A/en not_active IP Right Cessation
- 2010-04-23 CN CN201410119438.1A patent/CN103877030A/zh active Pending
- 2010-04-23 AU AU2010239085A patent/AU2010239085C1/en not_active Ceased
- 2010-04-23 KR KR1020147034848A patent/KR20150008909A/ko not_active Ceased
- 2010-04-23 SG SG10201401720RA patent/SG10201401720RA/en unknown
- 2010-04-23 KR KR1020117027887A patent/KR20120104489A/ko not_active Ceased
- 2010-04-23 JP JP2012506288A patent/JP6116244B2/ja active Active
- 2010-04-23 NZ NZ626401A patent/NZ626401A/en not_active IP Right Cessation
-
2011
- 2011-10-23 IL IL215868A patent/IL215868A0/en unknown
- 2011-10-24 TN TNP2011000536A patent/TN2011000536A1/en unknown
- 2011-11-23 CO CO11160580A patent/CO6470806A2/es not_active Application Discontinuation
- 2011-11-24 ZA ZA2011/08648A patent/ZA201108648B/en unknown
-
2014
- 2014-01-21 US US14/160,463 patent/US20140200276A1/en not_active Abandoned
- 2014-11-24 US US14/552,413 patent/US20150087709A1/en not_active Abandoned
-
2015
- 2015-05-20 JP JP2015102945A patent/JP6177275B2/ja not_active Expired - Fee Related
- 2015-07-14 US US14/799,438 patent/US20150313857A1/en not_active Abandoned
-
2016
- 2016-04-07 US US15/093,667 patent/US20160220518A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015166379A5 (enExample) | ||
| JP2015157851A5 (enExample) | ||
| JP2009529055A (ja) | エゼチミベ組成物 | |
| KR20100117097A (ko) | 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물 | |
| CN104546747A (zh) | 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法 | |
| CN106551912B (zh) | 一种提高难溶性药物溶出度的方法 | |
| NZ626401A (en) | A novel formulation of naproxen | |
| CN102438610A (zh) | 双氯芬酸的新剂型 | |
| WO2018064191A1 (en) | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
| JP6966780B2 (ja) | アセトアミノフェン製剤の製造方法 | |
| US20140335176A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
| JP7106161B2 (ja) | 粒子サイズが不揃いな原薬粒子の処理方法 | |
| US20190314349A1 (en) | Pyridone derivative pharmaceutical composition and preparation method thereof | |
| CN103933004B (zh) | 一种来曲唑片剂及其制备方法 | |
| CN102626410A (zh) | 一种含有罗氟司特的药物组合物 | |
| CA2492156C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
| JP5651478B2 (ja) | 糖アルコールと共微粒子化されたエンタカポンの医薬組成物 | |
| CN101623311A (zh) | 微粉化维参锌及其药物组合物 | |
| CN103877064B (zh) | 一种非诺贝特胶囊剂及其制备工艺 | |
| CN104306346A (zh) | 一种布南色林的缓释制剂及其制备方法 | |
| JP2018177800A (ja) | プレミックス原薬の製造方法 | |
| CN104257611A (zh) | 一种含微粉化盐酸非索非那定的药物组合物 | |
| JP7115825B2 (ja) | エゼチミブ含有経口製剤及びその製造方法 | |
| CN106236727A (zh) | 一种安乃近泡腾片及其制备方法 | |
| CN104337783A (zh) | 一种卡培他滨片剂及其制备方法 |